EUDA holds the exclusive global distributorship rights for Helixé products, that includes but is not limited to, a next-generation immune health supplement, from Chemokine, a Singapore-based biotech company focused on molecular supplements and gene-modulating formulations.

Regenixé Mask is formulated with iPSC-derived skin stem cell secretome technology and cellulose mask technology designed to support skin hydration, brightening, and overall recovery. EUDA believes secretome-based skincare products represent a growing category within the premium beauty and wellness market. According to Mordor Intelligence's Face Mask Market Report, the global face mask market is estimated to be approximately US$7.95 billion in 2026 and is forecast to reach approximately US$9.08 billion by 2031, driven by growing consumer demand for skincare, beauty, and wellness products. Asia-Pacific remains one of the largest regions for facial masks and skincare products, led by demand from China, South Korea, Japan, and Southeast Asia.

EUDA intends to leverage its established distribution networks and regional wellness partnerships in Malaysia and China to drive sales and distribution of the Regenixé Mask and expand the broader Helixé product line across the Asia-Pacific region.

EUDA Health Holdings Limited ("EUDA" and the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities ("MVLS") of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).

On May 28, 2026, the Company received a written notice from Nasdaq stating that the Company's Market Value of Listed Securities has been $35 million or greater for ten consecutive business days from May 13 to May 27, 2026, and therefore the Company has regained compliance with the MVLS requirement for continued listing on the Nasdaq Capital Market.